Long-Acting IL-2 Analog Conjugate for Lower-Toxicity Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current interleukin-2 (IL-2) therapies for immune-related conditions are limited by severe toxicity and side effects, restricting their application to a small number of patients, and there is a need for drugs that can reduce dosage while maintaining efficacy.
Innovation Solution
Development of a long-acting interleukin-2 analog conjugate with increased binding affinity for IL-2 beta receptors, comprising an IL-2 analog modified with specific amino acid substitutions and a polyethylene glycol linker attached to an immunoglobulin Fc region, enhancing its pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose interleukin-2 therapy is administered to achieve effective immune activation, then anticancer treatment efficacy is improved, but severe toxicity and side effects increase
Solution Approach 1:
The patent introduces amino acid substitutions at specific positions (e.g., L12V, L12F, L18R, L19Y, L20V, L20F, L20L, L22E, L32C, L35C, L38A, L38D, L42K, L42A, L43Q, L43C, L45A, L48C, L49C, L61Q, L61R, L61D, L68Q, L68D, L74H, L74A, L80F, L80L, L80V, L80Y, L81E, L81D, L82G, L82V, L84E, L85V, L85L, L85Y, L86V, L86A, L86G, L86I, L87C, L88Q, L88V, L89F, L91T, L91F, L92F, L92I, L94F, L94V, L96F, L96I, L125S, L126T) to selectively enhance binding affinity for IL-2Rβ while reducing affinity for IL-2Rα, thereby localizing the therapeutic effect to CD8+ T cells and NK cells and reducing systemic toxicity
Solution Approach 2:
The patent changes the binding affinity parameters of the IL-2 analog by introducing specific amino acid substitutions that modify the interaction with receptor subunits. The analogs are designed to have increased binding affinity for IL-2Rβ (CD122) and decreased affinity for IL-2Rα (CD25), altering the pharmacological profile to achieve selective immune activation with reduced toxicity
2Object-affected harmful factors
If interleukin-2 dosage is reduced to minimize toxicity, then side effects are decreased, but treatment efficacy is compromised
Solution Approach 1:
The IL-2 analogs exhibit selective binding characteristics that concentrate therapeutic effect on target cells (CD8+ T cells and NK cells expressing IL-2Rβ) while sparing other cell types. This selective action allows lower dosages to achieve the same therapeutic effect with reduced off-target toxicity
Solution Approach 2:
The patent creates composite therapeutic agents by combining modified IL-2 analogs with polyethylene glycol (PEG) linkers and immunoglobulin Fc regions. This composite structure extends circulation half-life and enhances pharmacokinetic properties, allowing sustained therapeutic effect at lower doses
3Reliability
If conventional interleukin-2 is used to activate immune cells, then immune activation is achieved, but administration convenience is poor due to frequent dosing required
Solution Approach 1:
The PEGylated IL-2 analogs with Fc region extensions provide sustained release and prolonged circulation in the bloodstream. The conjugate structure maintains continuous immune activation over extended periods, eliminating the need for frequent administrations and improving patient compliance
Data Source
AI summary
The present invention relates to a long-acting conjugate of an interleukin-2 analog with altered binding affinity for interleukin-2 receptors.